Press Releases AllArgonaut TherapeuticsBlogCelleron TherapeuticsEvents & PresentationsIngenOxNewsPress Releases Interim Phase 2 Results Suggest Zabadinostat Combination Improves Overall Survival in Advanced Liver Cancer February 26, 2025 IngenOx Therapeutics Chief Medical Officer Meets Chinese Premier to Advance International Anti-Cancer Cooperation February 10, 2025 IngenOx Therapeutics CMO Receives China Friendship Medal October 21, 2024 IngenOx Therapeutics Company Update and Board Reshuffle May 10, 2024 IngenOx Therapeutics Contributes to Review of Diagnostic Biomarkers for Precision Bowel Cancer Adjuvant Therapy December 7, 2023 IngenOx Therapeutics Receives Granted Patents from the EU and China for PRMT5 Inhibitor-based Drugs. October 6, 2023 IngenOx Therapeutics Receives New Patents for Compounds Inhibiting PRMT5 July 6, 2023 IngenOx Therapeutics Zabadinostat Approved by Hong Kong Drug Office to Start Liver Cancer Clinical Trial April 24, 2023 IngenOx Therapeutics Drug Zabadinostat Enhances the Immune Response March 7, 2023 Celleron Therapeutics and Argonaut Therapeutics Announce Completion of Merger to Form IngenOx Therapeutics January 5, 2023 Celleron Therapeutics founder David Kerr CBE receives major Chinese award November 8, 2022 Celleron Therapeutics Co-founder Professor David Kerr awarded Fellowship of ESMO September 22, 2022 Celleron Therapeutics partnered programme receives funding for investigating zabadinostat in immune checkpoint inhibitor resistant liver cancer August 15, 2022 Celleron Therapeutics reports 3-year survival data from Phase II clinical trial in MSS colorectal cancer patients treated with zabadinostat and nivolumab combination June 29, 2022 Argonaut Therapeutics Presents at BioTrinity 2022 Conference April 28, 2022 Celleron Therapeutics reports over 2-year survival of cancer patient treated with zabadinostat monotherapy April 7, 2022 Celleron Therapeutics reports survival data from zabadinostat combined with nivolumab in micro-satellite stable colorectal cancer patients January 20, 2022 Celleron Therapeutics Deploys a Digital Pathology Biomarker Platform in Pivotal Colorectal Cancer Clinical Study November 30, 2021 Celleron Therapeutics Appoints Corporate Governance Expert, Katherine Innes Ker, To Board November 8, 2021 Celleron Therapeutics appoints global financier Richard Taylor as new Board Director September 27, 2021 Celleron Therapeutics announces James Noble as new Board Chairman August 25, 2021 1 2 3 4 Next »
